drugset
drugset / Trial / NCT05758519

A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19

NCT05758519 ↗

Phase 3 Unknown 1220 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 3 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19

Timeline

Start
2023-03-07
Primary completion
2023-06-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject QLS1128 Unknown — Oral

Indications

COVID-19